Akebia Therapeutics ((AKBA)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Akebia Therapeutics’ latest earnings call struck a cautiously optimistic tone, as management highlighted a strong first full year of Vafseo commercialization, robust revenue growth and a reinforced cash position, even as they acknowledged slower-than-hoped uptake in the back half of 2025 and looming generic pressure on legacy drug Auryxia.
Revenue Surges on Vafseo Launch and Auryxia Strength
Total revenues climbed to $236.2 million in 2025 from $160.2 million in 2024, representing about 47% year-over-year growth driven by the U.S. debut of Vafseo and solid Auryxia performance. Net product revenue from both drugs reached $227 million, underscoring Akebia’s transition into a more commercially scaled business.
Vafseo Launch Delivers Early but Modest Traction
Vafseo contributed $45.8 million in net product revenue for 2025, including $6.2 million in the fourth quarter, reflecting meaningful but still early-stage adoption. Management framed these figures against a roughly $1 billion dialysis market opportunity post‑TDAPA, underscoring both the potential upside and the execution challenge ahead.
Expanding Prescriber Base and Clinic Access
More than 1,000 prescribers across 24 dialysis organizations have now written Vafseo prescriptions, signaling widening professional acceptance. In the fourth quarter alone about 800 prescribers wrote scripts, including 128 new writers, while clinic protocols now give roughly 290,000 dialysis patients access to the drug.
Adherence Metrics Trend Strongly Higher
Akebia reported notably improving adherence, a key driver of recurring revenue and real‑world efficacy. First‑refill adherence rose from around 75% earlier in 2025 to roughly 91% among an observed‑dosing subset in the fourth quarter, with early 2026 data showing sustained high‑80s to 90s adherence into subsequent refills.
Clinical and Economic Data Bolster Vafseo’s Value Story
Post‑hoc analysis from the INNO2VATE program suggested Vafseo may reduce the risk of death or hospitalization compared with ESA therapy in dialysis patients. Health‑economic modeling indicated a 7.7% lower annual hospitalization rate, 16% fewer hospital days and roughly 15% lower Medicare hospitalization costs, implying about $3,700 in savings per patient per year.
Balance Sheet Strengthens with Extended Runway
Cash and cash equivalents jumped to $184.8 million at year‑end 2025 from $51.9 million a year earlier, an increase of about $133 million. Management said this liquidity, combined with ongoing operations, should fund planned activities for at least the next two years, giving Akebia room to execute its commercial and clinical strategy.
Pipeline Builds with Multiple Near-Term Catalysts
Beyond Vafseo, Akebia highlighted an emerging pipeline that could diversify revenue in the next several years. Key milestones include the VOCAL trial of three‑times‑weekly Vafseo dosing with data expected in late 2026, VOICE data in early 2027 and new programs such as AKB‑097, praliciguat and AKB‑9090 advancing through Phase II and Phase I studies.
Profitability Trends Improve as Loss Narrows Sharply
The company’s net loss narrowed dramatically to $5.3 million in 2025 from $69.4 million in 2024, reflecting operating leverage from higher product revenue. Fourth‑quarter net loss improved to $12.2 million from $22.8 million a year earlier, despite stepped‑up investment in R&D and commercial infrastructure.
Vafseo Demand Flattens and Q4 Revenue Disappoints
Management acknowledged that Vafseo demand flattened in the second half of 2025, with quarterly demand hovering around $11–12 million and translating to just $6.2 million of recognized net revenue in Q4. This slower‑than‑expected uptake against a large target market signals that converting access and clinical data into rapid market share gains will take time.
Inventory Drawdown Weighs on Reported Results
Fourth‑quarter Vafseo revenue was also depressed by a one‑time inventory adjustment tied to a major partner’s shift to in‑center observed dosing. Akebia said the USRC transition triggered a distribution change that produced an estimated $4.8 million inventory drawdown, widening the gap between underlying demand and reported revenue.
R&D Spending Jumps on Pipeline Investments
Research and development expenses more than doubled in the fourth quarter to $26.6 million and climbed to $62.4 million for 2025, partly due to a $12.8 million acquired in‑process R&D charge for AKB‑097. While this raised near‑term cash burn, management framed the spending as essential to building a broader renal and cardio‑renal franchise.
Auryxia Faces Mounting Generic Headwinds
The legacy Auryxia franchise still generated $181.5 million in 2025 net revenue but is moving into a more competitive phase. Management warned that as generic competition broadens beyond the currently authorized generic, Auryxia revenues are expected to decline in 2026, increasing Akebia’s reliance on Vafseo and its pipeline.
Need for Peer-Reviewed Data to Unlock Further Adoption
Although management showcased positive clinical and economic findings for Vafseo, they emphasized that many physicians want peer‑reviewed publications before fully changing practice patterns. Until more data from VOCAL, VOICE and other analyses appear in the literature, Akebia’s ability to drive faster uptake will rest heavily on measured medical affairs activity.
Guidance Signals Operational Discipline and Execution Focus
While Akebia did not issue formal revenue guidance, it outlined key operating markers for investors to track, from Vafseo demand levels and adherence trends to prescriber growth and clinic protocol rollouts. The company reiterated that cash on hand should sustain operations for at least two years, flagged expected Auryxia revenue erosion in 2026 and highlighted upcoming clinical readouts that could reshape the growth profile.
Akebia’s earnings call painted the picture of a company moving firmly into commercial mode with a growing flagship product, a healthier balance sheet and a pipeline that could extend its renal footprint. The near term will likely be defined by the pace of Vafseo adoption and managing Auryxia’s decline, but the strategic direction and data backdrop left management sounding more confident than cautious about the road ahead.